0000950170-24-013482.txt : 20240209
0000950170-24-013482.hdr.sgml : 20240209
20240209194701
ACCESSION NUMBER: 0000950170-24-013482
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240209
FILED AS OF DATE: 20240209
DATE AS OF CHANGE: 20240209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gollob Jared
CENTRAL INDEX KEY: 0001821198
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 24617020
MAIL ADDRESS:
STREET 1: C/O KYMERA THERAPEUTICS, INC.
STREET 2: 200 ARSENAL YARDS, SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
ownership.xml
4
X0508
4
2024-02-09
0001815442
Kymera Therapeutics, Inc.
KYMR
0001821198
Gollob Jared
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
false
true
false
false
Chief Medical Officer
true
Common Stock
2024-02-09
4
M
false
46137
2.08
A
120846
D
Common Stock
2024-02-09
4
S
false
38739
35.3922
D
82107
D
Common Stock
2024-02-09
4
S
false
7398
36.0926
D
74709
D
Stock Option (Right to Buy)
2.08
2024-02-09
4
M
false
46137
0.00
D
2029-05-22
Common Stock
46137
62883
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
/s/ Bruce Jacobs, as Attorney-in-Fact
2024-02-09